Last Updated: November 16, 2026

POLIVY Drug Profile

« Back to Dashboard


Summary for Tradename: POLIVY
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for POLIVY
Recent Clinical Trials for POLIVY

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University College, LondonPhase 2
Hoffmann-La RochePhase 2
Washington University School of MedicinePhase 1/Phase 2

See all POLIVY clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for POLIVY Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for POLIVY Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for POLIVY Derived from Patent Text Search

These patents were obtained by searching patent claims

Polivy Market Dynamics and Financial Trajectory: Roche’s CD79b Antibody-Drug Conjugate

Last updated: October 27, 2026

Polivy, Roche’s polatuzumab vedotin, has moved from a niche relapsed diffuse large B-cell lymphoma treatment to a frontline regimen with potential blockbuster status. The key commercial event was the April 2023 FDA approval of Polivy plus rituximab, cyclophosphamide, doxorubicin and prednisone, or R-CHP, for previously untreated diffuse large B-cell lymphoma and high-grade B-cell lymphoma in patients with an International Prognostic Index score of at least 2.[1]

Roche reported Polivy sales of approximately CHF 1.0 billion in 2023, up sharply from roughly CHF 0.6 billion in 2022. The frontline indication expanded the addressable population beyond patients who had failed prior therapy and shifted Polivy toward use in the largest treatment line for DLBCL.[2]

What is Polivy and how does it work?

Polivy is an antibody-drug conjugate composed of:

Component Function
Polatuzumab antibody Binds CD79b on B cells
Valine-citrulline linker Releases the payload after intracellular processing
Monomethyl auristatin E, or MMAE Disrupts microtubules and causes cell death

The drug is administered intravenously. Its principal commercial market is B-cell non-Hodgkin lymphoma, particularly diffuse large B-cell lymphoma, the most common aggressive lymphoma subtype.

Polivy initially received accelerated FDA approval in June 2019 for relapsed or refractory DLBCL after at least two prior therapies, in combination with bendamustine and rituximab.[3] The FDA converted the product’s status into a broader frontline approval in April 2023 based on the POLARIX Phase 3 trial.[1]

How large is the Polivy market opportunity?

The commercial opportunity expanded materially after the frontline approval.

Relapsed and refractory DLBCL

Before 2023, Polivy was primarily used in patients with heavily pretreated DLBCL. This population has high unmet medical need but limited treatment duration and substantial competition from:

  • Autologous stem-cell transplantation
  • CD19-directed CAR-T therapies
  • Bispecific antibodies
  • Other salvage chemotherapy regimens

The relapsed setting produces high value per treated patient but a relatively small volume of eligible patients.

First-line DLBCL

The R-CHP regimen places Polivy in competition with R-CHOP, the established first-line standard. Polivy replaces vincristine in the regimen while retaining rituximab, cyclophosphamide, doxorubicin and prednisone.

The POLARIX trial enrolled 879 patients with previously untreated intermediate- or high-risk DLBCL. At two years, progression-free survival was 76.7% with Polivy-R-CHP versus 70.2% with R-CHOP. The progression-free survival hazard ratio was 0.73.[4]

Overall survival has not shown the same degree of separation. This limits the ability of Roche to position Polivy as a universal replacement for R-CHOP. Adoption depends on physician interpretation of the progression-free survival benefit, regimen familiarity, reimbursement and guideline positioning.

Estimated commercial structure

Polivy’s first-line market is larger than its relapsed-market base, but annual revenue depends on treatment duration, country mix and the rate at which physicians substitute Polivy-R-CHP for R-CHOP.

Market factor Commercial effect
Newly diagnosed DLBCL Expands patient volume substantially
Six-cycle frontline regimen Creates repeat dosing over a defined treatment course
Competition from low-cost R-CHOP Limits price and substitution
Hospital-administered infusion Supports controlled distribution but increases site-of-care complexity
DLBCL relapse Preserves demand for later-line treatment
CAR-T and bispecific competition Restricts Polivy use in some relapsed patients

What is Polivy’s financial trajectory?

Roche’s reported sales indicate rapid commercial acceleration after frontline approval.

Fiscal year Polivy sales, approximately Main commercial context
2020 CHF 0.17 billion Early accelerated-approval use
2021 CHF 0.28 billion Growth in relapsed/refractory DLBCL
2022 CHF 0.57 billion Broader uptake before and around frontline launch
2023 CHF 1.04 billion First full commercial year with frontline approval

Sources report Polivy sales in Roche’s financial statements in Swiss francs and may present growth on different currency bases. The direction is clear: revenue rose by about sixfold from 2020 to 2023, with the largest step-up occurring after the 2023 FDA expansion.[2]

Revenue trajectory scenarios

The base commercial case is continued growth followed by stabilization as frontline penetration matures.

Scenario Key assumptions Revenue implication
Upside Strong conversion from R-CHOP, durable international uptake, limited erosion in relapsed disease Polivy approaches or exceeds multibillion-franc annual sales
Base Moderate frontline adoption, continued R-CHOP use, stable reimbursement Growth continues before reaching a mature plateau
Downside Weak overall-survival differentiation, treatment-center resistance, pricing pressure and bispecific competition Revenue plateaus near early blockbuster levels

Polivy’s economics are supported by a large first-line population, but the product does not have an unlimited treatment duration. A typical frontline course is six cycles, which creates predictable but finite revenue per patient. That differs from chronic oncology medicines in which patients remain on therapy for many months or years.

When does Polivy lose regulatory exclusivity?

Polivy’s regulatory exclusivity depends on the applicable FDA and international protections.

United States biologic exclusivity

Polivy received its initial biologics license in June 2019. Under the Biologics Price Competition and Innovation Act, the reference product generally receives 12 years of reference-product exclusivity from first licensure. On that basis, the principal U.S. biologic exclusivity period runs to approximately June 2031, subject to the FDA’s determination of the first licensure date and any statutory interpretation affecting the product.[5]

The 2023 frontline approval does not ordinarily create a new 12-year reference-product exclusivity period because it was an expansion of an already licensed biologic.

Orphan-drug exclusivity

Polivy’s initial DLBCL indication also received orphan-drug treatment. Orphan exclusivity generally lasts seven years from approval for the protected indication. The initial orphan period would have begun in 2019 and reached its seven-year endpoint in 2026, subject to the precise scope of the designation and approval.[3]

Orphan exclusivity does not prevent all competing products from entering the market. It primarily blocks FDA approval of the same drug for the same disease or condition during the protected period, subject to statutory exceptions.

Patent exclusivity

Polivy is protected by patent families covering elements such as:

  • The antibody-drug conjugate
  • Anti-CD79b antibodies
  • Linker-payload chemistry
  • Conjugation and drug-to-antibody-ratio controls
  • Pharmaceutical compositions
  • Therapeutic use in B-cell malignancies
  • Manufacturing and formulation processes

A single expiration date cannot be assigned to the entire Polivy patent estate. The relevant date depends on the asserted patent, patent-term adjustment, patent-term extension, terminal disclaimers and the specific claim challenged.

What is the Orange Book status of Polivy?

Polivy does not have a conventional Orange Book listing because it is a biologic, not a small-molecule drug approved through a standard New Drug Application. Its regulatory reference-product and biosimilar information is handled through the FDA’s Purple Book and the Biologics Price Competition and Innovation Act framework.[5]

The absence of an Orange Book listing does not mean the product lacks patent protection. It means that biosimilar applicants address patent issues through the BPCIA patent-exchange process rather than through the small-molecule Hatch-Waxman Paragraph IV process.

Are there Paragraph IV challenges to Polivy?

Paragraph IV litigation is generally associated with abbreviated new drug applications for small-molecule products. A biosimilar applicant seeking to challenge Polivy would use the BPCIA framework, not a conventional Paragraph IV certification.

The principal U.S. competitive risk therefore comes from:

  1. A biosimilar application referencing polatuzumab vedotin.
  2. Patent litigation under the BPCIA.
  3. A potential launch after statutory exclusivity and patent barriers expire.
  4. Clinical substitution pressure from alternative lymphoma regimens rather than a traditional generic tablet launch.

Publicly visible market activity through mid-2024 had not established Polivy as a mature biosimilar battleground comparable to trastuzumab, rituximab or adalimumab. The product’s relatively recent launch, complex ADC manufacturing and limited treatment duration reduce the near-term probability of broad biosimilar competition.

How strong is the Polivy patent estate?

The estate is commercially meaningful because Polivy is a complex ADC rather than a simple antibody. The most defensible barriers are likely to arise from overlapping claims covering the conjugate, linker-payload, antibody sequence, drug-to-antibody ratio, pharmaceutical composition and manufacturing controls.

Technical barriers to biosimilar development

A competing manufacturer must demonstrate comparability across:

  • Molecular structure
  • Antibody binding to CD79b
  • Conjugation profile
  • MMAE loading
  • Linker cleavage
  • Aggregation
  • Impurities
  • Pharmacokinetics
  • Immunogenicity
  • Cytotoxic activity

ADC development requires specialized analytical and manufacturing capabilities. Those requirements can delay entry even where a biosimilar pathway is legally available.

The patent estate is strongest during the period in which multiple claim categories remain enforceable. It becomes more vulnerable if core composition claims expire and remaining protection is limited to narrower use or process claims.

What patent litigation affects Polivy?

The principal litigation risk is likely to emerge when a biosimilar developer files a U.S. application and provides a patent notice under the BPCIA. Potential disputes could involve:

  • Validity of antibody and conjugate claims
  • Obviousness of the linker-payload structure
  • Written description and enablement
  • Patent-term calculations
  • Manufacturing claims
  • Whether a biosimilar can launch for all or only some indications

As of the available public record through mid-2024, Polivy had not generated the high-volume biosimilar litigation seen for older oncology biologics. Roche’s near-term risk was commercial substitution by competing lymphoma therapies rather than immediate patent-driven generic erosion.

Which companies are challenging Polivy commercially?

Polivy faces different competitors by treatment line.

Frontline DLBCL

The primary competitor is R-CHOP, supplied by multiple manufacturers and available with lower-cost rituximab biosimilars. Roche must persuade physicians that the progression-free survival advantage justifies the incremental cost and additional product complexity.

Relapsed or refractory DLBCL

Key competitors include:

Company Product Mechanism or modality Competitive role
Kite, a Gilead company Yescarta CD19 CAR-T Later-line and earlier-line aggressive lymphoma
Bristol Myers Squibb Breyanzi CD19 CAR-T Relapsed large B-cell lymphoma
Roche Columvi CD20xCD3 bispecific antibody Off-the-shelf treatment in relapsed DLBCL
Genmab and AbbVie Epkinly CD20xCD3 bispecific antibody Relapsed or refractory DLBCL
Various manufacturers Rituximab biosimilars Anti-CD20 antibody Lower-cost backbone therapy

Roche’s ownership of both Polivy and Columvi creates portfolio advantages. The company can offer an ADC in frontline treatment and a bispecific antibody in later-line disease, although the products also compete for internal commercial resources and treatment-center capacity.

How does Polivy compare with competing DLBCL therapies?

Attribute Polivy-R-CHP R-CHOP CAR-T therapy Bispecific antibody
Typical use First-line DLBCL First-line DLBCL Relapsed or selected earlier-line disease Relapsed disease
Administration Repeated IV infusions Repeated IV infusions One-time cellular therapy after manufacturing Repeated outpatient or inpatient dosing
Main evidence advantage Improved progression-free survival in POLARIX Long-established standard High response rates in selected patients Off-the-shelf treatment
Main limitation Cost and uncertain overall-survival differentiation Relapse risk Manufacturing, toxicity and treatment-center capacity Cytokine-release syndrome and repeated dosing
Biosimilar exposure Medium to long term High Low Low in the near term

Polivy has the strongest commercial position when used before relapse, when treatment-center logistics are simpler and the competing standard is R-CHOP. CAR-T therapies are more differentiated but remain resource-intensive. Bispecific antibodies are easier to deploy than CAR-T but compete directly with Polivy in later-line disease.

What FDA regulatory milestones shape Polivy’s market?

Date Milestone
June 2019 FDA accelerated approval for relapsed or refractory DLBCL after at least two prior therapies
2020 European Union conditional approval for relapsed or refractory DLBCL
April 2023 FDA approval with R-CHP for previously untreated DLBCL and high-grade B-cell lymphoma in eligible patients
2023 onward Commercial expansion into first-line treatment and broader guideline-driven use

The 2023 FDA decision is the central driver of Polivy’s revenue trajectory. It converted Polivy from a later-line specialty product into a frontline regimen with a much larger eligible population.[1]

What generic or biosimilar launch risks exist?

Near-term entry risk is limited by the product’s biologic status, technical complexity and relatively recent initial approval. The principal medium-term risks are:

  • A biosimilar filing after the reference-product exclusivity period
  • Patent litigation over ADC composition and manufacturing claims
  • Rituximab biosimilar substitution reducing the value of the combination regimen
  • R-CHOP price competition
  • New bispecific antibodies moving into earlier lines
  • CAR-T therapies moving into first-line or second-line treatment
  • Clinical data failing to show a durable overall-survival benefit

Polivy is more exposed to therapeutic displacement than to conventional generic substitution. A competing regimen that produces similar outcomes at a lower total cost could reduce Polivy use before formal biosimilar entry.

What licensing deals support Polivy?

Polivy incorporates technology from the antibody-drug conjugate ecosystem, including vedotin linker-payload technology associated with Seagen. Roche and Seagen entered into a strategic ADC collaboration covering multiple programs, including polatuzumab vedotin.[6]

The commercial effect is that Roche controls the product and global commercialization while third-party technology rights may create royalty or contractual payment obligations. Those obligations reduce net economics relative to a fully internally owned product, but they do not appear to have prevented Roche from achieving blockbuster-scale sales.

What is the outlook for Polivy revenue?

Polivy has the potential to remain a major Roche oncology product through the late 2020s. Its growth depends on three variables:

  1. The percentage of newly diagnosed DLBCL patients treated with Polivy-R-CHP.
  2. The durability of the progression-free survival advantage relative to R-CHOP.
  3. The pace of competition from bispecific antibodies, CAR-T therapies and future targeted regimens.

Roche’s strongest commercial argument is convenience: Polivy can be added to an established frontline chemoimmunotherapy platform without the manufacturing delay and specialized infrastructure required for CAR-T therapy.

The main constraint is evidence differentiation. POLARIX improved progression-free survival but did not establish a decisive overall-survival advantage in the initial analysis. If later follow-up confirms a survival benefit, adoption could accelerate. If the benefit remains limited to disease control, payers and physicians may reserve Polivy for higher-risk patients.

Key Takeaways

  • Polivy is Roche’s polatuzumab vedotin CD79b antibody-drug conjugate.
  • The April 2023 FDA frontline approval changed Polivy’s commercial profile.
  • Roche reported approximately CHF 1.04 billion in Polivy sales in 2023, up from about CHF 0.57 billion in 2022.
  • The largest market is first-line DLBCL, where Polivy-R-CHP competes with R-CHOP.
  • The POLARIX trial showed a progression-free survival benefit but no equivalent initial overall-survival separation.
  • Polivy has no conventional Orange Book listing because it is a biologic; U.S. reference-product issues are handled through the Purple Book and BPCIA framework.
  • Approximate U.S. biologic exclusivity runs to 2031 based on the 2019 first licensure date.
  • The principal near-term threat is therapeutic substitution by R-CHOP, bispecific antibodies and CAR-T therapies, not a conventional generic launch.
  • ADC manufacturing complexity and layered composition, use and process patents support a meaningful medium-term barrier to biosimilar entry.
  • Polivy has a credible path to sustained blockbuster sales, but peak revenue depends on frontline adoption and evidence of durable clinical benefit.

FAQs About Polivy Market Exclusivity and Competition

Is Polivy a biologic or a small-molecule drug?

Polivy is a biologic antibody-drug conjugate. It combines a monoclonal antibody with a cytotoxic MMAE payload.

What drug replaced vincristine in the Polivy regimen?

Polivy replaces vincristine in the R-CHP regimen. Rituximab, cyclophosphamide, doxorubicin and prednisone remain in the combination.

Does Polivy have an FDA-approved biosimilar?

No FDA-approved Polivy biosimilar had been established in the public record through mid-2024.

What is the main clinical risk to Polivy sales?

The main risk is limited differentiation from R-CHOP if Polivy’s progression-free survival benefit does not translate into a durable overall-survival advantage.

Can Polivy be used with CAR-T therapy?

Polivy and CAR-T therapy occupy different treatment positions, although treatment sequencing may evolve as clinical trials move cellular therapies into earlier lines of DLBCL.

References

  1. U.S. Food and Drug Administration. (2023, April 19). FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma. https://www.fda.gov
  2. Roche Holding AG. (2024). Roche annual report 2023. https://www.roche.com
  3. U.S. Food and Drug Administration. (2019, June 10). FDA grants accelerated approval to polatuzumab vedotin-piiq for diffuse large B-cell lymphoma. https://www.fda.gov
  4. Tilly, H., Morschhauser, F., Sehn, L. H., Friedberg, J. W., Trněný, M., Shipp, M., et al. (2022). Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. New England Journal of Medicine, 386(4), 351-363.
  5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
  6. Seagen Inc. (2012). Seattle Genetics and Roche enter strategic collaboration to develop antibody-drug conjugates. https://www.seagen.com

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.